The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.
about
Cooperative epigenetic modulation by cancer amplicon genesMolecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathwaysInactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphomaHodgkin lymphoma and immunodeficiency in persons with HIV/AIDSCurrent trends in the treatment of primary mediastinal large B-cell lymphoma - an overviewUnexpected functions of nuclear factor-κB during germinal center B-cell development: implications for lymphomagenesisTargeting the B-cell receptor signaling pathway in B lymphoid malignanciesThe genetic landscape of diffuse large B-cell lymphomaNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewRadiotherapy for Non-Hodgkin's lymphoma: still standard practice and not an outdated treatment optionThe c-Rel transcription factor and B-cell proliferation: a deal with the devilThe Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service researchPrimary mediastinal B-cell lymphoma: treatment and therapeutic targetsTargeting NF-kappaB in hematologic malignanciesMHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancersc-Rel deficiency increases caspase-4 expression and leads to ER stress and necrosis in EBV-transformed cellsMature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.Diffuse large B-cell non-Hodgkin lymphoma involving the unilateral carotid space in an elderly man: A case report.Composite Lymphoma: Opposite Ends of Spectrum Meet.A loss-of-function RNA interference screen for molecular targets in cancer.A library of gene expression signatures to illuminate normal and pathological lymphoid biology.A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments.A large-scale rheumatoid arthritis genetic study identifies association at chromosome 9q33.2.Biomarker discovery across annotated and unannotated microarray datasets using semi-supervised learning.Classification of lymphoid neoplasms: the microscope as a tool for disease discovery.Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older.Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.Gray zones around diffuse large B cell lymphoma. Conclusions based on the workshop of the XIV meeting of the European Association for Hematopathology and the Society of Hematopathology in Bordeaux, France.Hodgkin lymphoma: an update on its biology with new insights into classification.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Comparison of pediatric and adult lymphomas involving the mediastinum characterized by distinctive clinicopathological and radiological features.The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.Oncogenic activation of NF-kappaB.Discriminating lymphomas and reactive lymphadenopathy in lymph node biopsies by gene expression profilingPathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.
P2860
Q24608701-14E30722-9E50-4C51-8BB7-5C5450CB8662Q24652565-30132D22-5B3B-48AE-AF7A-6F31F31CFB7DQ24676965-18E09CA5-295E-48F5-8E52-B8C8219B6556Q24685909-6B9F4A4A-96E8-48E2-A593-CDC09BED1148Q26769596-B9F7E372-5F3C-478A-9AB7-7B053964A22CQ26822486-0128E4BC-8DE7-4226-9E02-FA7FED9BDFDAQ26828782-F6815FA5-5D69-4158-87CF-BB63F5D94C07Q26866537-B9FEEA87-F170-49B1-9215-D0520269C60AQ27304386-7D22E0E5-0237-4F39-9485-EF76AF7C0F23Q28079951-9213D332-3471-4F61-8A8C-D426AE69C2ACQ28241767-A4DB0D38-521C-446E-9602-56229DB00BE1Q28266484-CD834F6D-18B0-4D5B-AFCB-7853F4E9DCAAQ28278652-B7147560-BB0B-4B71-8D47-6B2D02942E56Q28299055-1AB7DDEF-4A75-4B07-9743-59495AC9ED50Q28306431-5E1FBA76-7A09-476B-94ED-C36384823028Q28744344-47CC4CCA-A08D-4CD5-8ECB-9548C6AB7A97Q30240133-159FB7CB-BD35-418A-9D64-360C2AA522E0Q33168184-ED282200-B7A9-4520-A3B9-4E575925E02CQ33168244-4A157483-3767-4B1A-96EB-64E1BE2D3105Q33237976-1EE85686-68FB-46F2-A4B4-C92C0904849FQ33240316-F08559D6-6154-49DE-8A19-14E2DA13AE3EQ33314438-27DA7197-F886-4724-902C-7CA81BDDB3FFQ33354118-EAC88B49-857A-402E-894D-8B8E45F43D3EQ33373584-4183ADF2-3C88-44C1-AC2F-DBCBAA4FB78CQ33386690-71EA5340-8489-44B5-B62F-CA74233EDAB9Q33396833-DB5D3260-A587-4478-B58E-A95235D8B63FQ33406742-4B55BB36-D464-4BB2-96C5-049934090E13Q33432504-5E757C2D-9B20-4621-89C0-6A2A69970ADCQ33560762-8620FC94-4914-4D69-96AA-338E7429080DQ33588862-11358ACA-3FBE-4857-83A8-1DDFC02D6F20Q33622342-62A18994-C4AE-4822-ABB9-83E994BBAC18Q33632062-7536D693-B270-4219-B484-CC5C11169AC6Q33669371-F809E5ED-63A0-4723-A85C-4013FA95CA79Q33704061-24230B05-5BC4-4113-B1A5-08FF16504BEBQ33747063-1765CF55-500E-41C3-B8D6-760C3717114CQ33829419-60909425-7967-4D26-A881-3068EE7B6EF9Q33846801-57301C6A-DE68-4542-A6DF-1AB7DED5D62BQ33849388-06E91BE9-ED58-41E1-B1A2-F814253E9C69Q33858819-8A27A6AE-48C7-4840-9CCC-26BE54C90277Q33889168-AE298656-E8EA-44A9-AA73-B52928E49FC3
P2860
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
The molecular signature of med ...... th classical Hodgkin lymphoma.
@en
The molecular signature of med ...... th classical Hodgkin lymphoma.
@nl
type
label
The molecular signature of med ...... th classical Hodgkin lymphoma.
@en
The molecular signature of med ...... th classical Hodgkin lymphoma.
@nl
prefLabel
The molecular signature of med ...... th classical Hodgkin lymphoma.
@en
The molecular signature of med ...... th classical Hodgkin lymphoma.
@nl
P2093
P50
P1433
P1476
The molecular signature of med ...... ith classical Hodgkin lymphoma
@en
P2093
Christine Ladd
Donna Neuberg
Francoise Berger
Friedrich Feuerhake
Geraldine S Pinkus
Gilles Salles
Jeffery L Kutok
Jon C Aster
Kerry J Savage
Margaret A Shipp
P304
P356
10.1182/BLOOD-2003-06-1841
P407
P577
2003-08-21T00:00:00Z